Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life Background information
• Continuous subcutaneous insulin infusion (CSII) has been used for over 20 years to improve glycemic control in patients with diabetes in whom multiple daily injections of insulin have not been completely successful.
• A meta-analysis of 12 randomized clinical trials has shown that CSII is associated with improvements in levels of blood glucose and glycated hemoglobin (HbA 1c ) (Pickup et al. 2002) .
• However, it has been suggested that CSII might be less safe than injection therapy, with increases in the incidence of diabetic ketoacidosis.
Aims
• To study the efficacy, safety, patient acceptability and impact on quality of life of CSII therapy in patients with type 1 diabetes living in the Veneto region of Italy.
Methods
• A retrospective, uncontrolled analysis was performed in patients who had started CSII therapy within the previous 20 years at 11 centers in the Veneto region.
• HbA 1c levels, bodyweight, body mass index and insulin requirements were obtained from patients' medical notes before the start of CSII and every subsequent year.
• Ketoacidosis, severe hypoglycemia frequency, hospital admission details and outpatient visits were recorded from the start of diabetes to the present time.
• Other data (demographics, patient acceptability and quality of life, assessed using the Diabetes Quality-of-Life Measure [DQOL]) were obtained via questionnaires at the time of data collection.
Results
• 138 patients participated in the study. The mean age, duration of diabetes and duration of CSII therapy were 33.1 ± 1.0, 13.1 ± 0.7 and 7.4 ± 0.4 years, respectively. • HbA 1c levels and daily insulin requirements decreased significantly during the first year of CSII and remained unchanged over the following years.
• Episodes of severe hypoglycemia and ketoacidosis decreased significantly after switching from insulin injection therapy to CSII (Table 1) , the latter possibly because of technological improvements in infusion devices and better patient education. DCCT Research Group 1988) , patients' mean bodyweight increased after the switch to CSII therapy, and the change was significant from the third year of CSII therapy onwards.
Key points
• Patient acceptability of CSII therapy was very high, with 78.4% of patients expressing a desire to continue with treatment. Benefits of CSII therapy cited by patients included improvements in metabolic control and greater flexibility with meals (Figure 1 ). • The DQOL questionnaire was completed by 98 patients. The overall score of 73.0 ± 1.8 suggested a high level of well-being among patients receiving CSII therapy.
''
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Conclusions
• In a retrospective analysis of > 100 patients in Veneto, Italy, CSII therapy was associated with improvements in glycemic control, and reductions in hypoglycemia, diabetic ketoacidosis, insulin requirements, hospitalizations, and outpatient visits. • Patient acceptability of CSII therapy was good, and quality of life scores indicated a high level of well-being among patients treated with CSII. 
